Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 221Carcinoma, Non-Small-Cell Lung 218Prostatic Neoplasms 150Multiple Myeloma 140Neoplasms 129Colorectal Neoplasms 117Leukemia, Myeloid, Acute 106Lung Neoplasms 102Neoplasm Metastasis 95Squamous Cell Carcinoma of Head and Neck 91Carcinoma, Hepatocellular 84Lymphoma 78Melanoma 77Triple Negative Breast Neoplasms 71Pancreatic Neoplasms 71Ovarian Neoplasms 66Sarcoma 64Lymphoma, Large B-Cell, Diffuse 61Carcinoma, Renal Cell 59Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Head and Neck Neoplasms 57Recurrence 56Brain Neoplasms 56Lymphoma, Non-Hodgkin 53Hematologic Neoplasms 52Stomach Neoplasms 51Leukemia, Lymphocytic, Chronic, B-Cell 51Endometrial Neoplasms 50Small Cell Lung Carcinoma 48Rectal Neoplasms 46

Interventions

talazoparib 1atezolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Extensive Stage Lung Small Cell Carcinoma × 90 days × Clear all
NCT04334941 2026-06-05

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

National Cancer Institute (NCI)

Phase 2 Active not recruiting
103 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡